Neuralstem Inc. (CUR) CEO Richard J. Daly Purchases 35,715 Shares of Stock
Neuralstem Inc. (NASDAQ:CUR) CEO Richard J. Daly bought 35,715 shares of Neuralstem stock in a transaction that occurred on Friday, November 25th. The shares were acquired at an average price of $0.28 per share, for a total transaction of $10,000.20. Following the acquisition, the chief executive officer now directly owns 102,680 shares in the company, valued at approximately $28,750.40. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Neuralstem Inc. (NASDAQ:CUR) opened at 0.282 on Tuesday. Neuralstem Inc. has a 52-week low of $0.19 and a 52-week high of $1.20. The company’s market cap is $32.36 million. The stock has a 50 day moving average of $0.28 and a 200 day moving average of $0.29.
Neuralstem (NASDAQ:CUR) last released its quarterly earnings data on Tuesday, November 8th. The company reported ($0.05) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by $0.02. Neuralstem had a negative net margin of 170,366.66% and a negative return on equity of 4,420.33%. On average, equities analysts anticipate that Neuralstem Inc. will post ($0.19) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “Neuralstem Inc. (CUR) CEO Richard J. Daly Purchases 35,715 Shares of Stock” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US and international trademark and copyright laws. The original version of this piece can be read at http://www.dailypolitical.com/2016/11/29/neuralstem-inc-cur-ceo-richard-j-daly-purchases-35715-shares-of-stock.html.
A number of equities analysts have commented on the stock. Roth Capital reiterated a “buy” rating and issued a $1.20 price objective on shares of Neuralstem in a report on Thursday, November 10th. Aegis assumed coverage on shares of Neuralstem in a report on Monday, November 7th. They issued a “buy” rating on the stock. Finally, Brean Capital assumed coverage on shares of Neuralstem in a report on Tuesday, October 4th. They issued a “buy” rating and a $4.00 price objective on the stock.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in CUR. Blair William & Co. IL bought a new position in Neuralstem during the second quarter valued at $122,000. Vanguard Group Inc. raised its position in Neuralstem by 21.8% in the second quarter. Vanguard Group Inc. now owns 3,384,138 shares of the company’s stock valued at $984,000 after buying an additional 606,500 shares in the last quarter. Finally, Sabby Management LLC bought a new position in Neuralstem during the second quarter valued at $1,893,000. Hedge funds and other institutional investors own 10.77% of the company’s stock.
Neuralstem Company Profile
Neuralstem, Inc (Neuralstem) is a clinical-stage biopharmaceutical company. The Company is engaged in research, development and commercialization of central nervous system therapies based on its human neuronal stem cells and its stem-cell derived small molecule compounds. The Company has approximately three assets: its NSI-189 small molecule program, its NSI-566 stem cell therapy program and its chemical entity screening platform.
Receive News & Ratings for Neuralstem Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neuralstem Inc. and related companies with MarketBeat.com's FREE daily email newsletter.